Substance / Medication

Ceftriaxone

Overview

Active Ingredient
ceftriaxone
RxNorm CUI
2193

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

29 trials linked to this intervention

29
Total Trials
6
Recruiting
7
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Piperacillin/tazobactam versus ceftriaxone/metronidazole for children with perforated appendicitis: a systematic review and meta-analysis.
Armstrong Jennifer, Sriranjan Jhanahan, Briatico Daniel et al. · Pediatr Surg Int · 2025
PMID: 41186640Meta-Analysis
Ceftriaxone-induced cholelithiasis in pediatrics: pooled frequency, symptoms, and associated factors - systematic review and meta-analysis.
Yaseen Tahneem, Alam Khurshid, Zawiah Mohammed et al. · Ital J Pediatr · 2025
PMID: 41074174Meta-AnalysisFull text (PMC)
Pharmacokinetics of ceftriaxone, gentamicin, meropenem and vancomycin in liver cirrhosis: a systematic review.
Comce M H, Weersink R A, Beuers U et al. · J Antimicrob Chemother · 2024
PMID: 39289819Meta-AnalysisFull text (PMC)
Inappropriate ceftriaxone utilization and predictor factors in Ethiopia: a systematic review and meta-analysis.
Tafere Chernet, Endeshaw Destaw, Demsie Desalegn Getnet et al. · Sci Rep · 2024
PMID: 39443593Meta-AnalysisFull text (PMC)
Ceftriaxone-associated biliary pseudolithiasis in children: do we know enough?
Cuzzolin Laura, Oggiano Anna Maria, Clemente Maria Grazia et al. · Fundam Clin Pharmacol · 2021
PMID: 32492204Meta-Analysis
Safety of ceftriaxone in paediatrics: a systematic review.
Zeng Linan, Wang Chao, Jiang Min et al. · Arch Dis Child · 2020
PMID: 32144089Meta-AnalysisFull text (PMC)
Systematic review and survey of Neisseria gonorrhoeae ceftriaxone and azithromycin susceptibility data in the Asia Pacific, 2011 to 2016.
George C R Robert, Enriquez Rodney P, Gatus Barrie J et al. · PLoS One · 2019
PMID: 30943199Meta-AnalysisFull text (PMC)
Combination of Ceftriaxone and Ampicillin for the Treatment of Enterococcal Endocarditis: A Qualitative Systematic Review.
Peterson Shaylee C, Lau Tim T Y, Ensom Mary H H · Ann Pharmacother · 2017
PMID: 28166656Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Ceftriaxone (substance)
SNOMED CT
372670001
UMLS CUI
C0007561
RxNorm CUI
2193

Clinical Data

This intervention maps to 20 entities in the Ltrl knowledge graph.

20
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
29
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.